| Samuel Douglas, PT, DPT | |
|
3300 Webster St Ste 703, Oakland, CA 94609-3122 | |
| (510) 835-5633 | |
| Not Available |
| Full Name | Samuel Douglas |
|---|---|
| Gender | Male |
| Speciality | Physical Therapy |
| Experience | 3 Years |
| Location | 3300 Webster St Ste 703, Oakland, California |
| Accepts Medicare Assignments | May be. He may accept the Medicare-approved amount; you may be billed for more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1356003867 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208100000X | Physical Medicine & Rehabilitation | 300980 (California) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Taylor And Thornburg Physical Therapy, Inc. | 4789753880 | 10 |
News Archive
An increasing number of digital mental health interventions are designed for adolescents and young people with a range of mental health issues, but the evidence on their effectiveness is mixed, according to research by Columbia University Mailman School of Public Health and Spark Street Advisors.
Merck & Co., Inc. priced today a $2.5 billion public offering of senior unsecured notes.
Researchers from Huntsman Cancer Institute (HCI) at the University of Utah report that they have identified a previously undiscovered trigger mechanism for a quality control checkpoint at the very end of the cell division process in a paper to be published in the November 29 issue of The Journal of Cell Biology and online today.
The ROMaN Project, Inc. announces its endorsement of the Food and Drug Administration's (FDA) guidance to utilize risk-based monitoring in clinical trials. Risk-based monitoring focuses attention to the most critical data elements in a study and allocates monitoring resources to the investigator sites with problematic or unproven protocol compliance and/or data integrity.
Oncolytics Biotech Inc. today announced that the first patients have been treated in a Phase 1b study of pembrolizumab (KEYTRUDA) in combination with REOLYSIN (pelareorep) and chemotherapy in patients with advanced pancreatic adenocarcinoma (REO 024).
› Verified 9 days ago
| Entity Name | Physiotherapy Associates Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1003822586 PECOS PAC ID: 3577470442 Enrollment ID: O20080328000335 |
News Archive
An increasing number of digital mental health interventions are designed for adolescents and young people with a range of mental health issues, but the evidence on their effectiveness is mixed, according to research by Columbia University Mailman School of Public Health and Spark Street Advisors.
Merck & Co., Inc. priced today a $2.5 billion public offering of senior unsecured notes.
Researchers from Huntsman Cancer Institute (HCI) at the University of Utah report that they have identified a previously undiscovered trigger mechanism for a quality control checkpoint at the very end of the cell division process in a paper to be published in the November 29 issue of The Journal of Cell Biology and online today.
The ROMaN Project, Inc. announces its endorsement of the Food and Drug Administration's (FDA) guidance to utilize risk-based monitoring in clinical trials. Risk-based monitoring focuses attention to the most critical data elements in a study and allocates monitoring resources to the investigator sites with problematic or unproven protocol compliance and/or data integrity.
Oncolytics Biotech Inc. today announced that the first patients have been treated in a Phase 1b study of pembrolizumab (KEYTRUDA) in combination with REOLYSIN (pelareorep) and chemotherapy in patients with advanced pancreatic adenocarcinoma (REO 024).
› Verified 9 days ago
| Entity Name | Taylor & Thornburg Physical Therapy, Inc. |
|---|---|
| Entity Type | Part B Supplier - Physical/occupational Therapy Group In Private Practice |
| Entity Identifiers | NPI Number: 1679759203 PECOS PAC ID: 4789753880 Enrollment ID: O20080515000229 |
News Archive
An increasing number of digital mental health interventions are designed for adolescents and young people with a range of mental health issues, but the evidence on their effectiveness is mixed, according to research by Columbia University Mailman School of Public Health and Spark Street Advisors.
Merck & Co., Inc. priced today a $2.5 billion public offering of senior unsecured notes.
Researchers from Huntsman Cancer Institute (HCI) at the University of Utah report that they have identified a previously undiscovered trigger mechanism for a quality control checkpoint at the very end of the cell division process in a paper to be published in the November 29 issue of The Journal of Cell Biology and online today.
The ROMaN Project, Inc. announces its endorsement of the Food and Drug Administration's (FDA) guidance to utilize risk-based monitoring in clinical trials. Risk-based monitoring focuses attention to the most critical data elements in a study and allocates monitoring resources to the investigator sites with problematic or unproven protocol compliance and/or data integrity.
Oncolytics Biotech Inc. today announced that the first patients have been treated in a Phase 1b study of pembrolizumab (KEYTRUDA) in combination with REOLYSIN (pelareorep) and chemotherapy in patients with advanced pancreatic adenocarcinoma (REO 024).
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Samuel Douglas, PT, DPT 515 Vernon St Apt 203, Oakland, CA 94610-1402 Ph: (510) 292-8669 | Samuel Douglas, PT, DPT 3300 Webster St Ste 703, Oakland, CA 94609-3122 Ph: (510) 835-5633 |
News Archive
An increasing number of digital mental health interventions are designed for adolescents and young people with a range of mental health issues, but the evidence on their effectiveness is mixed, according to research by Columbia University Mailman School of Public Health and Spark Street Advisors.
Merck & Co., Inc. priced today a $2.5 billion public offering of senior unsecured notes.
Researchers from Huntsman Cancer Institute (HCI) at the University of Utah report that they have identified a previously undiscovered trigger mechanism for a quality control checkpoint at the very end of the cell division process in a paper to be published in the November 29 issue of The Journal of Cell Biology and online today.
The ROMaN Project, Inc. announces its endorsement of the Food and Drug Administration's (FDA) guidance to utilize risk-based monitoring in clinical trials. Risk-based monitoring focuses attention to the most critical data elements in a study and allocates monitoring resources to the investigator sites with problematic or unproven protocol compliance and/or data integrity.
Oncolytics Biotech Inc. today announced that the first patients have been treated in a Phase 1b study of pembrolizumab (KEYTRUDA) in combination with REOLYSIN (pelareorep) and chemotherapy in patients with advanced pancreatic adenocarcinoma (REO 024).
› Verified 9 days ago
Dr. Allison Gannon Pollock, M.D. Physical Medicine & Rehabilitation Medicare: Medicare Enrolled Practice Location: 350 Hawthorne Ave, Oakland, CA 94609 Phone: 510-847-7771 | |
Andrea Lee Wilcox, MD Physical Medicine & Rehabilitation Medicare: Medicare Enrolled Practice Location: 275 W Macarthur, Oakland, CA 94611 Phone: 510-752-1000 | |
Margaret Cosgrove, DPT Physical Medicine & Rehabilitation Medicare: Medicare Enrolled Practice Location: 3600 Broadway, Oakland, CA 94611 Phone: 510-752-1000 | |
Alexandria Woodbury, Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 3645 Grand Ave Ste 203, Oakland, CA 94610 Phone: 510-883-3534 | |
Yumi Mitsuya, M.D. Physical Medicine & Rehabilitation Medicare: Medicare Enrolled Practice Location: 747 52nd St, Oakland, CA 94609 Phone: 510-428-3000 | |
Margaret Lucy Stokely, OTR/L Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 44 Danbury St, Oakland, CA 94605 Phone: 423-243-4743 | |
Chiachen Hsu, MD Physical Medicine & Rehabilitation Medicare: Medicare Enrolled Practice Location: 275 W Macarthur Blvd, Oakland, CA 94611 Phone: 510-752-1000 |